Brian L. Hood

Gynecologic Oncology Group — United States

Chemistry · Physical Sciences

44h-index6.3kcitations239works1.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Proteomics Techniques and Applications(48), Molecular Biology Techniques and Applications(31), Ovarian cancer diagnosis and treatment(25), Cancer, Lipids, and Metabolism(21), Mass Spectrometry Techniques and Applications(18)

Publications239 total

Serum adenosine deaminase 2 predicts chemotherapy response and survival in advanced high-grade serous ovarian carcinoma
Gynecologic Oncology·2026
Abstract A057: Integrated proteogenomics uncovers ancestry-specific and shared molecular drivers in localized prostate cancer
Cancer Research·2026
ShapeUpLMD: An Automated Pipeline for Spatially Optimized Laser Microdissection in Multi-omic Tissue Profiling
2025Open Access
IDENTIFYING RESPONDERS TO ENZALUTAMIDE IN ADVANCED ENDOMETRIAL CANCER: THE ENPAC STUDY
International Journal of Gynecological Cancer·2025
Quantitative proteomics identifies conserved proteins and altered regulation of mucin-16 in low grade serous ovarian cancers
Clinical Proteomics·2025Open Access
EP.03.01 Identification and Validation of Recurrence-Associated Proteins in Stage I Lung Adenocarcinoma
Journal of Thoracic Oncology·2025
Silva pattern-guided proteomics reveals coordinated tumor-stroma remodeling in cervical adenocarcinoma
Gynecologic Oncology·2025
Quantitative proteomic analyses of the tumor microenvironment in cervical adenocarcinomas by silva pattern
Gynecologic Oncology·2025
Proteogenomic characterization of invasive breast tumors in young women
npj Breast Cancer·2025· 3 citedOpen Access
Histology-resolved proteomics reveals distinct tumor and stromal profiles in low- and high-grade prostate cancer
Clinical Proteomics·2025· 1 citedOpen Access
PRX-3140, a 5-HT4 Partial Agonist and Sigma-1 Agonist/Antagonist, Modulates Glucocorticoid Insulin Suppression and Cortisol Levels
2024Open Access
Deep quantitative proteomics identifies elevated MUC16 in low- compared to high-grade serous ovarian carcinoma
Gynecologic Oncology·2024
Impact of the tumor microenvironment in splenic metastasis in high-grade serous ovarian cancer revealed by quantitative proteomics
Gynecologic Oncology·2024
Molecular markers of response to enzalutamide-based therapy in advanced or recurrent endometrioid endometrial adenocarcinoma (ENPAC study)
Gynecologic Oncology·2024
TRANSTHYRETIN (TTR) AS NON-INVASIVE DIAGNOSTIC MARKER TO DIFFERENTIATE UTERINE LEIOMYOSARCOMA FROM UTERINE FIBROIDS
Fertility and Sterility·2024Open Access
Multiomic analysis of uterine leiomyomas in self-described Black and White women: molecular insights into health disparities
American Journal of Obstetrics and Gynecology·2024· 7 cited
Author Correction: Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities
npj Precision Oncology·2024Open Access
Quantitative Proteomics Identifies Conserved Proteins and Altered Regulation of Mucin-16 in Low Grade Serous Ovarian Cancers
2024Open Access
Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities
npj Precision Oncology·2024· 7 citedOpen Access
Abstract PR-012: Proteogenomic analysis of enriched tumor epithelium identifies prognostic signatures and an increased dependency of homologous recombination proficient cells on bmi1 in high grade serous ovarian cancer
Cancer Research·2024
page 1 of 12Next →

Frequent Co-authors

Thomas P. Conrads(49), Timothy D. Veenstra(19), Nicholas W. Bateman(11), G. Larry Maxwell(8), Mai Sun(8), Kelly A. Conrads(7), David B. Krizman(5), Guisong Wang(5), Pang-ning Teng(5), Marlene Darfler(4), David A. Lucas(4), Kathleen M. Darcy(4), Chad A. Hamilton(4), Lixin Mi(3), Xiantao Wang(3), Sudha Govind(3), Fung‐Lung Chung(3), Roger Day(3), Uma Chandran(3), Coralie Viollet(3)